Faron presents BEXMAB data at ASH Annual Meeting ...Middle East

Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Faron Presents Full Analysis of Positive Phase 2 Interim Data from BEXMAB Trial at the 66th American Society of Hematology (ASH) Annual Meeting Poster highlights Overall response rate of 80% (16 out of 20) in refractory or relapsed HMA...

Read More Details
Finally We wish PressBee provided you with enough information of ( Faron presents BEXMAB data at ASH Annual Meeting )

Also on site :

• Billboard’s 2025 Global Power Players Revealed
• Meghan Markle shares unseen family photos on seventh wedding anniversary to Prince Harry
• Are US-Israel ‘special relations’ about to end?